Llovet J M,？ Ricci S,？ Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,？ 2008, 359(4): 378-390. [2]Cheng A L,？ Kang Y K,？ Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:？ a phase Ⅲ randomised,？ double-blind,？ placebo-controlled trial[J]. Lancet Oncol,？ 2009, 10(1): 25-34.？ [3]Wilhelm S M,？ Carter C,？ Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res,？ 2004,？ 64(19):？ 7099-7109.？ [4]Wilhelm S M,？ Adnane L,？ Newell P, et al. Preclinical overview of sorafenib,？ a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling[J]. Mol Cancer Ther,？ 2008,？ 7(10): 3129-3140.？ [5]Liu L,？ Cao Y,？ Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway,？ inhibits tumor angiogenesis,？ and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res,？ 2006,？ 66(24): 11851-11858.？ [6] Ａbou-Alfa G K,？ Schwartz L,？ Ricci S, et al. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol,？ 2006,？ 24(26): 4293-4300.？ [7]Choi M S,？ Shim Y H,？ Hwa J Y, et al. Expression of DNA methyltransferases in multistep hepatocarcinogenesis[J]. Hum Pathol,？ 2003, 34(1): 11-17.？ [8]Zhang Z,？ Zhou X,？ Shen H, et al. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma:？ evidence from an ？in vitro？ study[J]. BMC Med,？ 2009,？ 7: 41. [9]Pinter M,？ Sieghart W,？ Hucke F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib[J]. Aliment Pharmacol Ther,？ 2011,？ 34(8): 949-959. [10]Worns M A,？ Weinmann A,？ Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis[J]. J Clin Gastroenterol,？ 2009,？ 43(5): 489-495.？ [11]Kim J E,？ Ryoo B Y,？ Ryu M H, et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function[J]. Cancer Chemother Pharmacol,？ 2011,？ 68(5): 1285-1290.？ [12]Baek K K,？ Kim J H,？ Uhm J E, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib:？ a retrospective comparison with previously known prognostic models[J]. Oncology, 2011,？ 80(3/4): 167-174.？ [13]Shim J H,？ Park J W,？ Choi J I, et al. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area[J]. J Cancer Res Clin Oncol,？ 2009,？ 135(4): 617-625.
